Prof. Ugur Sahin and Medine GmbH Report 15.8% Stake in BioNTech SE (Amendment No. 6)

This Amendment No. 6 to Schedule 13G, filed on May 15, 2026, reports the beneficial ownership of BioNTech SE (BNTX) by Medine GmbH and Prof. Ugur Sahin, M.D. As of the event date of March 31, 2026, Prof. Ugur Sahin is reported to beneficially own 40,076,320 ordinary shares, representing 15.8% of the company based on 252,884,261 shares outstanding. Medine GmbH, a German entity controlled by Prof. Sahin, holds 39,111,390 of these shares. The total beneficial ownership for Prof. Sahin also includes 858,209 shares held directly and 106,721 shares held by a former colleague over which he retains voting power through a written arrangement. Medine GmbH is deemed to beneficially own 39,218,111 shares (15.5%). The reporting persons share dispositive power over the 39,111,390 shares held by Medine GmbH. This filing updates previous disclosures regarding the ownership structure of BioNTech's co-founder and his investment vehicle.